content_top
43 companies, 1 interpreter! Insight, foresight
and recommendation 

MiMedx Group, Inc (MDXG)

14.34
0.10
(0.70%)
Sep 11, 4:00PM EDT
content_middle

MiMedx Group (MDXG), a biopharmaceutical company, develops and markets regenerative biologics utilizing human placental tissue allografts with patent-protected processes for various sectors of healthcare.

MDXG processes the human placental tissue utilizing its proprietary PURION Process to produce allografts. The company's proprietary processing methodology employs aseptic processing techniques in addition to terminal sterilization. Its biomaterial platform technologies include AmnioFix and EpiFix that are tissue technologies processed from human amniotic membrane derived from donated placental tissue for homologous applications; OrthoFlo, an amniotic fluid-derived allograft for homologous applications; Physio, a bone grafting material comprising 100% bone tissue with no added carrier; and CollaFix, a technology platform derived from collagen fiber technology designed to mimic the natural composition, structure, and mechanical properties of musculoskeletal tissues to augment their repair.

MDXG also offers EpiCord, an umbilical cord allograft that provides a connective tissue matrix to replace or supplement damaged or inadequate integumental tissue; AmnioCord, an umbilical cord allograft that offers a protective environment for the healing process; and AmnioFill, a cellular tissue matrix allograft that enhances healing.

Its products have applications in the areas of wound care, burns, surgery, orthopedics, spine, sports medicine, ophthalmology, and dentistry.

MiMedx Group, Inc. is headquartered in Marietta, Georgia.

Previous Close: 
14.24
Open: 
14.35
Bid: 
14.25
Ask: 
15.20
1yr Target Price: 
15.14
Day's Range: 
14.23 - 14.90
52wk Range: 
7.64 - 17.47
Volume: 
2432303
Average Daily Volume: 
1482280
Market Capitalization: 
1.54B
Trailing Annual Dividend Yield: 
N/A
Shares Outstanding: 
107280000M
content_right

Pages